NVAX — NOVAVAX INC

Nasdaq · Health Care · Biotechnology · CIK 1000694 ·
Last close
$10.46
Market Cap
$1.72B
52W High
$11.15
52W Low
$7.57
ADV30
4,889,049
Next earnings
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 139,514,000 108,819,000 -15,430,000 -9,491,000 1,043,162,000 228,363,000 1,187,924,000
Dec 2025 147,139,000 125,035,000 15,037,000 17,527,000 1,176,512,000 240,634,000 1,304,265,000
Sep 2025 70,445,000 48,949,000 -80,980,000 -202,379,000 1,179,889,000 268,023,000 1,336,561,000
Jun 2025 239,240,000 223,915,000 101,070,000 106,508,000 1,336,549,000 253,744,000 1,298,924,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-244,635,000
Investing CF
$-78,267,000
Financing CF
$27,737,000
CapEx
$-6,388,000
Dividends Paid
Buybacks
EPS Diluted TTM
$2.41
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,568,148,000
Inventory
$11,545,000
Receivables
$106,446,000
ST Investments
$494,450,000
EBIT TTM
$464,714,000
Pretax Income TTM
$442,167,000
Interest Exp TTM
$22,547,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$596,337,984
EBITDA
$59,532,000
Free Cash Flow
$58,573,936
Enterprise Value
$1,019,201,088
Total Cash
$790,332,032
Total Debt
$295,057,984
Shares Out
164,438,119
Trailing EPS
$-0.56
Book Value
$-0.79
ROE
ROA
2.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,123,479,000 550,640,000 440,302,000 1,176,512,000 1,304,265,000 -244,635,000
Dec 2024 682,162,000 -248,931,000 -187,499,000 1,560,418,000 2,184,259,000 -87,263,000
Dec 2023 556,382,000 -566,511,000 -545,062,000 1,797,490,000 2,514,417,000 -713,967,000
Dec 2022 1,598,951,000 -644,736,000 -657,939,000 2,258,679,000 2,892,757,000 -415,937,000

TTM Snapshot

Revenues TTM
$1,184,919,000
NetIncome TTM
$-743,120,000
OpCashFlow TTM
$0
Assets (Latest)
$1,560,418,000
Forward EPS
$-0.54

Peers — same industry

TickerNameMarket CapLastDaily %
VCEL Vericel Corp $1.79B $34.97
GLUE Monte Rosa Therapeutics, Inc. $1.62B $19.20
IOVA IOVANCE BIOTHERAPEUTICS, INC. $1.83B $4.10
TSHA Taysha Gene Therapies, Inc. $1.61B $5.59
VIR Vir Biotechnology, Inc. $1.58B $9.38

News headlines (Yahoo Finance, 1h cache)

Why Novavax (NVAX) Stock Is Trading Up Today
2026-05-26 20:15 · Yahoo
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
2026-05-26 13:00 · Yahoo
3 Reasons NVAX is Risky and 1 Stock to Buy Instead
2026-05-25 15:15 · Yahoo
Assessing Novavax (NVAX) Valuation As Trading Swings Revive Investor Interest
2026-05-18 11:09 · Yahoo
3 Small-Cap Stocks That Fall Short
2026-05-18 11:00 · Yahoo
GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know
2026-05-17 10:12 · Yahoo
The Top 5 Analyst Questions From Novavax’s Q1 Earnings Call
2026-05-16 20:12 · Yahoo
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
2026-05-12 13:00 · Yahoo
Moderna Stock Loses Steam. Hantavirus Trade Fizzles as Officials Dismiss Pandemic Risk.
2026-05-11 19:18 · Yahoo
Novavax (NVAX) Is Up 25.9% After Pfizer Matrix-M Deal And Q1 Beat On Expectations - What's Changed
2026-05-11 18:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.